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Introducing Alzheimer’s & Dementia: Diagnosis, Assessment & Disease
Monitoring, an open access journal of the Alzheimer’s AssociationWelcome to the inaugural issue of Alzheimer’s & Demen-
tia: Diagnosis, Assessment & Disease Monitoring (DADM)
(http://ees.elsevier.com/dadm/default.asp), an open access
journal of the Alzheimer’s Association. The journal will
concentrate on new research that reports the discovery,
development, and validation of assays, instruments, technol-
ogies, and algorithmic approaches leading to the accurate
detection and tracking of individuals at risk of progressive
dementing diseases. The reports to be published in this jour-
nal will cover a range of topics focused on the early and
accurate detection of individuals with memory complaints
and/or asymptomatic individuals at elevated risk of various
forms of memory disorders. All forms of biomarkers will
be considered, ranging from gene expression and proteomic
markers, to imaging, cognitive and functional markers of
disease progression or treatment response.
The launch nearly 1 decade ago of Alzheimer’s & Demen-
tia: The Journal of the Alzheimer’s Association (A&D)
increased the capacity for “translational knowledge” in the
field.A&D has investedmany editorial pages spanning trans-
lational topics, including imaging [1,2], genetics [3–11],
diagnostic instrumentation and development [12–16],
biomarker discovery [17–24], and biomarker validation
[25–32]. A&D has focused specifically on the limitations
of prevailing paradigms and research challenges that will
spur therapy development. As the field continues to grow,
additional channels are necessary to help researchers
communicate more specialized findings to a growing
multi-disciplinary audience. The journal’s expansion to
include an open-access publishing model allows for such
added capacity.
DADMwill drive scientific advances by creating linkages
between the discovery and validation of novel biomarkers.
Furthermore, the Journal will report on the application of
biomarkers to more sensitively and reliably diagnose disease
(including the preclinical disease burden), assess disease
severity, and monitor progression both in the clinic and
within the context of clinical trials. The expectation for sub-
mitted reports will be to translate fundamental knowledge
about the biology and/or clinical features of the disease
into practical reports that describe efforts to systematically
validate biomarkers that will serve to advance our field.http://dx.doi.org/10.1016/j.dadm.2015.01.001
2352-8729/ 2015 The Alzheimer’s Association. Published by Elsevier Inc. T
creativecommons.org/licenses/by-nc-nd/4.0/).Article topics should explore the development of biomarkers
(broadly defined, and including cognitive, imaging, physio-
logic, and biochemical approaches), surrogate markers, and
conceptual/methodologic challenges. Publication priority
will be given to reports that (1) describe putative surrogate
markers that accurately track disease progression and/or
treatment response, (2) explore the validity and reliability
of biomarkers that have the potential to fulfill international
regulatory requirements, (3) use data from large, well-
characterized population-based cohorts that encompass the
heterogeneity, geographical, and ethnic diversity of asymp-
tomatic individuals, and/or (4) develop advanced algorithms
that consider multimarker arrays (e.g., integrated-omics,
genetics, biofluids, imaging) and advanced computational
analytics and technologies.
DADMwill publish comprehensive literature reviews that
serve to expand the state of knowledge, occasional edito-
rials, and perspectives. In addition, the Journal will make
full use of the electronic publication format—including a
web portal to the Alzheimer’s & Dementia Resource Center
(AlzDem.Org)—all intended to challenge editors, reviewers,
authors, and readers to consider the methods and technolo-
gies as a pathway to inform deeper understanding of the dis-
ease and its natural history.
As an online-only open access journal,DADM has several
advantages compared with standard print journals. In addi-
tion to a rapid review process, the journal will issue DOI
identifiers to all accepted articles within 1 month of final
manuscript acceptance. In addition to publishing fully
composed articles within 30 days of acceptance, DADM
will also be able to publish accompanying video clips
(when appropriate), full color graphics for figures, and
more extensive use of imaging to accompany the accepted
articles.1. Why publish in an open access journal?
There are already many venues available to publish
exciting new research, and yet Alzheimer’s & Dementia is
still unable to publish all the excellent reports submitted
for consideration. The new open access journals of the Alz-
heimer’s Association are tied directly to the A&D editorialhis is an open access article under the CC BY-NC-ND license (http://
P.J. Snyder / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 1–42office, with shared representation on the editorial boards and
integrated communication among all the editors with respect
to identifying the best vehicle for the publication of each
manuscript that meets our high level of editorial review.
Also, clear advantages exist to authors for publishing in
the new open access journals. A recent study conducted by
the British Research Information Network (available at:
www.researchinfonet.org) analyzed the web traffic to more
than 700 articles published in hybrid science journal Nature
Communications, during the first 6 months of 2013. Author-
sponsored articles as open access papers were viewed more
than twice as often as those articles that were only accessible
to the journal’s paid subscribers. Moreover, an additional
analysis of more than 2000 reports published inNature Com-
munications between April 2010 and June 2013 revealed
that open access articles were cited a median of 11 times
compared with a median of 7 citations for subscription-
only articles [33].2. How was the journal’s title chosen?
The title of DADM is intended to map directly on to the
new classification system promoted by the National Institute
of Aging, the Alzheimer’s Association, and several other
international funders of Alzheimer’s disease research from
North America, Europe, Asia, and Oceania [34]. This “com-
mon Alzheimer’s disease research ontology” (CADRO) is
organized around seven [7] major categories of grant-
supported activities. The second of these seven categories
is “diagnosis, assessment, and disease monitoring.” To
help promote this international classification system, this
title was selected for the new journal with the belief that
the CADRO classifications will become the standard by
which both governmental and private philanthropic funding
agencies will categorize all award information for the pur-
pose of sharing across agencies, as acknowledged recently
by the International Funders Group (Alzheimer’s Associa-
tion International Conference, Boston, July 2013). As
such, the editors believe that the use of this classification sys-
tem for publications will be of assistance to both funding
agencies and authors/investigators who will increasingly
need to demonstrate how their work maps onto the CADRO
ontology.3. Publication in DADM
Similar to its parent journal, Alzheimer’s & Dementia:
Diagnosis, Assessment & Disease Monitoring will focus
on publishing:
 Comprehensive review articles
 Original research papers
 Short reports
 Abstracts of reports presented at select international
meetings
 In-depth perspectives Theoretical and/or translational reports that attempt to
integrate knowledge across disciplines
 Special issues on specific topics of high interest to the
readership
In addition, to take full-advantage of its electronic pub-
lishing approach and web platforms, this journal will publish
 Occasional and striking images (both artistic and
those resulting from laboratory work, clinical prac-
tice, and neuroimaging) that are provocative and
informative—any reader may submit such images for
consideration
 Special talks, videos, and slide sets
 Occasional sets of reports that actively encourage
debate on controversial issues
 Reports that could be tangential to the core focus of
biomarker development/validation but that are, none-
theless, of high interest to our readers.
Our hope and intent is to create a novel forum for rapid
communication and to foster both dialogue and cross-
fertilization of ideas between disciplines.
As noted, DADM will consider novel works, meta-
analyses, and systematic reviews covering a wide range of
topics, including, but not limited, to
 Neuroimaging, systems physiology, and functional
neuroanatomy
 Genomics and epigenetics
 Neurochemistry and peripheral biochemical markers
 Cognitive neuroscience, clinical neuropsychology, and
behavioral neurology4. The editorial team
The editor-in-chief of Alzheimer’s & Dementia: Diag-
nosis, Assessment & Disease Monitoring, is Dr. Peter J.
Snyder. Drs. Ara Khachaturian and Kathleen Hayden
will be serving as the executive editors of DADM. In
addition, the senior editorial team includes five highly
accomplished leaders in our field who will serve as
Senior Associate Editors: Drs. Liana Apostolova (Geffen
School of Medicine, University of California, Los
Angeles), Stefan Teipel (University of Rostock, Rostock,
Germany), Henrik Zetterberg (University of Gothenburg,
Gothenburg, Sweden), Paul Maruff (CogState, Ltd., and
University of Melbourne, Melbourne, Australia), and
Richard Jones (Alpert Medical School of Brown Univer-
sity, Providence, RI). These Senior Associate Editors
provide both depth and breadth of knowledge in the
field and allow for a balanced and experienced senior
leadership team. We are also joined by two skilled
Statistical Editors, Drs. Jason T. Machan (Rhode Island
Hospital and Alpert Medical School of Brown Univer-
sity, Providence, RI) and Stephen W. Hurt (New York–
Presbyterian Hospital and Weill Cornell Medical
College, New York, NY).
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guidance, support, and continual advice of Dr. Zaven Kha-
chaturian (Editor-in-Chief, Alzheimer’s & Dementia), Dr.
Ara Khachaturian (Executive Editor, Alzheimer’s & Demen-
tia and the Alzheimer’s & Dementia open access journal
portfolio), Dr. Lon Schneider (Editor-in-Chief, Alzheimer’s
& Dementia: Translational Research & Clinical Interven-
tions), Dr. Kathleen Hayden (Senior Associate Editor,
Alzheimer’s & Dementia and Executive Editor, Alzheimer’s
& Dementia open access journal portfolio), Mr. Terry
Materese (Executive Publisher, Elsevier), and Dr. Maria
Carrillo (Vice President of Medical and Scientific Relations,
Alzheimer’s Association).
Finally, the DADM editorial board is composed of more
than 30 experienced, talented, and respected scientists and
clinicians, all of whom have agreed to serve as active mem-
bers of our editorial board (available at: http://ees.elsevier.
com/dadm/default.asp). These individuals were selected
because they are international opinion leaders who will
provide comprehensive coverage of all relevant disciplines
and because they are enthusiastic about contributing to the
growth of the Alzheimer’s & Dementia family of journals.
The editors of Alzheimer’s & Dementia: Diagnosis,
Assessment & Disease Monitoring hope that readers will
enjoy and benefit from these first open access articles and
that readers will consider becoming published authors in
this new journal.Peter J. Snyder
Editor-in-Chief*
Department of Neurology
Alpert Medical School of Brown University
and Lifespan Hospital System
Providence, RI, USA
*Corresponding author. Tel.: 11-401-444-4117.
E-mail address: Editor_DADM@lifespan.org
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